Strategic Partners A/S - Share Issue/Capital Change 2017

Orphazyme A/S: Stabilisation measures taken

Orphazyme A/S: Stabilisation measures taken


Company announcement No. 14/2017	Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 24 November 2017

NOT
FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

This announcement does not constitute an
offering circular and nothing herein contains an offering of securities.

With
reference to the company announcement no. 7/2017 dated 16 November 2017 regarding
the beginning of the stabilisation period following the initial public offering
and admission to trading and official listing of the temporary purchase
certificates and the shares of Orphazyme A/S ("Orphazyme") on Nasdaq Copenhagen
(the "Offering" or the "IPO"), Orphazyme has received notification that Danske
Bank, acting as stabilising manager in the Offering, has taken the
stabilisation measures set out in the attached notification with respect to the
temporary purchase certificates and the shares of Orphazyme.

For
additional information, please contact

Orphazyme


Anders Hinsby, CEO	+45 31 44 31 39

Impact
Partners


Michael Steen-Knudsen	+45 25 17 18 15

Important
notice

This
announcement is not an offer to sell or a solicitation of any offer to buy any
securities issued by Orphazyme A/S ("Orphazyme" or the "Company") in any
jurisdiction where such offer or sale would be unlawful and the announcement
and the information contained herein are not for distribution or release,
directly or indirectly, in or into such jurisdictions, including but not
limited to, the United States, Australia, Canada and Japan.

This
announcement does not constitute, or form part of, an offer to sell, or a
solicitation of an offer to purchase, any securities in the United States. The
securities referred to herein have not been and will not be registered under
the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not
be offered or sold within the United States absent registration or to an
exemption from, or in a transaction not subject to, the registration
requirements of the Securities Act. There is no intention to register any securities
referred to herein in the United States or to make any offering of the
securities in the United States.

In
any member state of the European Economic Area ("EEA Member State"), other than
Denmark, that has implemented Directive 2003/71/EC as amended (together with
any applicable implementing measures in any member State, the "Prospectus
Directive"), this communication is only addressed to and is only directed at
investors in that EEA Member State who fulfil the criteria for exemption from
the obligation to publish an offering memorandum, including qualified
investors, within the meaning of the Prospectus Directive as implemented in
each such EEA Member State.

This
announcement is only being distributed to and is only directed at (i) persons
who are outside the United Kingdom or (ii) to investment professionals falling
within Article 19(5) of the U.K. Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities
falling within Article 49(2)(a) - (d) of the Order (the persons described in
(i) through (iii) above together being referred to as "relevant persons"). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in
only with, relevant persons. Any person who is not a relevant person should
not act or rely on this document or any of its contents.

In
connection with the offering, Danske Bank A/S (the "Stabilising Manager") (or
persons acting on behalf of the Stabilising Manager) may over-allot securities
or effect transactions with a view to supporting the market price of the
securities at a level higher than that which might otherwise prevail. However,
there is no assurance that the Stabilising Manager (or persons acting on behalf
of the Stabilising Manager) will undertake stabilisation. Any stabilisation
action may begin on or after the date of commencement of trading and official
listing of the securities on Nasdaq Copenhagen A/S and, if begun, may be ended
at any time, but it must end no later than 30 days after the date of
commencement of trading and official listing of the securities.

Matters
discussed in this announcement may constitute forward-looking statements.
Forward-looking statements are statements that are not historical facts and
that can be identified by words such as "believe", "expect", "anticipate",
"intends", "estimate", "will", "may", "continue", "should", and similar
expressions. The forward-looking statements in this announcement are based upon
various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors that are difficult or impossible to predict and are beyond its control.
Such risks, uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations expressed or
implied in this release by such forward-looking statements. The information,
opinions and forward-looking statements contained in this announcement speak
only as at its date, and are subject to change without notice.

NOT
FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY
OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

24
November 2017

Orphazyme
A/S (ticker: ORPHA) (the "Company")

Mid-Stabilisation
Period Notice

Further
to the pre-stabilisation period announcement dated 16 November 2017, Danske Bank A/S
(Niels Erik Nielsen, telephone +44 (0)20 7410 8070) hereby gives notice that
the Stabilisation Manager named below undertook stabilisation (within the
meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) in
relation to the offer of the following securities, as set out below;


The securities:
Issuer:	Orphazyme A/S
Securities:	Temporary Purchase Certificates (DK0060911055) until 20 November 2017 and Ordinary shares (DK0060910917) thereafter
Offering size:	8,625,000 shares of DKK 1 nominal value each
Offer price:	DKK 80 per share
Market:	Nasdaq Copenhagen (XCSE)
Ticker:	ORPHA TEMP (temporary purchase certificates) ORPHA (ordinary shares)

Stabilisation Manager:	Danske Bank A/S Holmens Kanal 1-12 1092 København K Denmark
Maximum size of over-allotment facility:	Up to 1,125,000 shares

Summary
of daily stabilisation transactions


Date	Price (lowest)	Price (highest)	Price (weighted average)	Quantity	Currency	Market
16 Nov 2017	79.0	80.0	79.9244	812,820	DKK	Nasdaq Copenhagen
17 Nov 2017	79.5	80.0	79.9952	47,640	DKK	Nasdaq Copenhagen
20 Nov 2017	79.5	80.0	79.9249	80,000	DKK	Nasdaq Copenhagen
21 Nov 2017	79.5	80.0	79.7169	45,000	DKK	Nasdaq Copenhagen
22 Nov 2017	79.5	80.0	79.5676	30,000	DKK	Nasdaq Copenhagen
23 Nov 2017	78.0	79.5	78.9195	14,500	DKK	Nasdaq Copenhagen
24 Nov 2017	76.5	79.5	77.7857	21,000	DKK	Nasdaq Copenhagen